Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies

ABSTRACT Background: Cardiovascular trials using clinical endpoints to assess efficacy typically require followup of large numbers of participants for 3–5 years. This disadvantage has encouraged the search for well-validated surrogate markers for cardiovascular disease (CVD). These markers may provide earlier indications of efficacy in trials involving fewer participants. One approach gaining interest in recent years is the measurement of atherosclerotic progression, a major underlying cause of CVD. Scope: This review article aims to further substantiate the evidence supporting the use of measurement of carotid intima-media thickness (CIMT) as a surrogate marker for atherosclerosis and cardiovascular risk. Findings: CIMT has consistently been related to future CVD events in population studies. CIMT is significantly related with other markers for CVD risk, such as elevated levels of risk factors and presence of atherosclerosis in the coronary arteries. Furthermore, almost all lipid-lowering trials and a large number of blood pressure lowering trials have consistently shown a reduction in progression of CIMT. In addition, the ultrasound technique for measuring CIMT is safe and highly reproducible. Conclusion: Thus, CIMT may be used as a surrogate endpoint in clinical trials to enable the benefits of new therapies or regimens to be more rapidly translated into clinical practice.

[1]  G. Berglund,et al.  Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.

[2]  H. Crijns,et al.  Effects of Nifedipine on Carotid and Femoral Arterial Wall Thickness in Previously Untreated Hypertensive Patients , 2003, Blood pressure. Supplement.

[3]  Hafiz M. R. Khan,et al.  Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. , 2005, Atherosclerosis.

[4]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[5]  W. Gropp,et al.  Accepted for publication , 2001 .

[6]  B. Mulder,et al.  Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair. , 2006, American heart journal.

[7]  A. Keren,et al.  Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. , 1997, The American journal of cardiology.

[8]  Aaron Fenster,et al.  3D Ultrasound Measurement of Change in Carotid Plaque Volume: A Tool for Rapid Evaluation of New Therapies , 2005, Stroke.

[9]  P. Sager,et al.  Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. , 2005, American heart journal.

[10]  J. Tardif,et al.  Intravascular ultrasound assessment of atherosclerosis , 2004, Current atherosclerosis reports.

[11]  J. Salonen,et al.  Determinants of carotid intima‐media thickness: a population‐based ultrasonography study in Eastern Finnish men , 1991, Journal of internal medicine.

[12]  H. Putter,et al.  Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. , 2004, Diabetes care.

[13]  E. Topol,et al.  Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. , 1995, Circulation.

[14]  J. McNeil,et al.  The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[15]  M. Matsuhisa,et al.  Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. , 2000, Diabetes care.

[16]  A. Algra,et al.  Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. , 2006, European heart journal.

[17]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[18]  G. Gamble,et al.  Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. , 1998, Circulation.

[19]  N Bom,et al.  An in vitro evaluation of the line pattern of the near and far walls of carotid arteries using B-mode ultrasound. , 1996, Ultrasound in medicine & biology.

[20]  A. Folsom,et al.  Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. , 2000, American journal of epidemiology.

[21]  Y. Yamasaki,et al.  Recent Advances of Intervention to Inhibit Progression of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes Mellitus , 2006, Stroke.

[22]  G. Moneta.  Carotid Intima-Media Thickening Indicates a Higher Vascular Risk Across a Wide Age Range: Prospective Data From the Carotid Atherosclerosis Progression Study (CAPS) , 2008 .

[23]  D. Rader,et al.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.

[24]  D. Grobbee,et al.  Atherosclerotic disease regression with statins: studies using vascular markers. , 2004, International journal of cardiology.

[25]  J. Staessen,et al.  Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials , 2006, Stroke.

[26]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[27]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[28]  A. Nicolaides,et al.  Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study , 1998, Diabetes Care.

[29]  M. Trip,et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.

[30]  M. Bots,et al.  Low concentrations of folate, not hyperhomocysteinemia, are associated with carotid intima-media thickness. , 2005, Atherosclerosis.

[31]  Aaron Fenster,et al.  Quantification of carotid plaque volume measurements using 3D ultrasound imaging. , 2005, Ultrasound in medicine & biology.

[32]  E. Tuzcu,et al.  Recent trends in coronary intravascular ultrasound: Tracking atherosclerosis, pursuit of vulnerable plaques, and beyond , 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[33]  T. Craven,et al.  Prognostic Significance of Progression of Coronary Atherosclerosis , 1993, Circulation.

[34]  A. Smit,et al.  Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. , 2004, Circulation.

[35]  P. Schoenhagen,et al.  Intravascular ultrasonography: using imaging end points in coronary atherosclerosis trials. , 2005, Cleveland Clinic journal of medicine.

[36]  R. Mattace,et al.  Intimal-medial thickness of the common carotid arteries and lower limbs atherosclerosis in the elderly. , 1999, Minerva cardioangiologica.

[37]  Y. Yamasaki,et al.  Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study) , 2006, Cardiovascular diabetology.

[38]  Vance W Berger,et al.  Does the Prentice criterion validate surrogate endpoints? , 2004, Statistics in medicine.

[39]  Matthias W. Lorenz,et al.  Carotid Intima-Media Thickening Indicates a Higher Vascular Risk Across a Wide Age Range: Prospective Data From the Carotid Atherosclerosis Progression Study (CAPS) , 2006, Stroke.

[40]  Allen J. Taylor,et al.  ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness , 2002, Circulation.

[41]  A. Folsom,et al.  Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. , 1997, American journal of epidemiology.

[42]  Eary,et al.  CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS , 2000 .

[43]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[44]  B M Psaty,et al.  Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. , 1991, Stroke.

[45]  Alberto Balbarini,et al.  Usefulness of Carotid Intima-Media Thickness Measurement and Peripheral B-Mode Ultrasound Scan in the Clinical Screening of Patients with Coronary Artery Disease , 2000, Angiology.

[46]  J. Edelstein,et al.  Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[47]  S. Azen,et al.  Alpha-Tocopherol Supplementation in Healthy Individuals Reduces Low-Density Lipoprotein Oxidation but Not Atherosclerosis: The Vitamin E Atherosclerosis Prevention Study (VEAPS) , 2002, Circulation.

[48]  D. Grobbee,et al.  The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. , 2003, Controlled clinical trials.

[49]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[50]  H. Lakka,et al.  Six-Year Effect of Combined Vitamin C and E Supplementation on Atherosclerotic Progression: The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study , 2003, Circulation.

[51]  Michiel L. Bots,et al.  Intima Media Thickness as a Surrogate Marker for Generalised Atherosclerosis , 2002, Cardiovascular Drugs and Therapy.

[52]  J. Witteman,et al.  Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. , 1999, Maturitas.

[53]  E. Tuzcu,et al.  Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. , 2006, American heart journal.

[54]  D J Sheridan,et al.  The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. , 1994, European heart journal.

[55]  D. Grobbee,et al.  The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. , 2004, European heart journal.

[56]  A. Seifalian,et al.  A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. , 2002, Cardiovascular research.

[57]  A. Smit,et al.  Effects of amlodipine and lisinopril on intima–media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial) , 2004, Journal of hypertension.

[58]  J. Gardin,et al.  American Society of Echocardiography recommendations for use of echocardiography in clinical trials. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[59]  S. Anderssen,et al.  Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. , 2005, Atherosclerosis.

[60]  J. Collet,et al.  Surrogate endpoints: A basis for a rational approach , 2006, European Journal of Clinical Pharmacology.

[61]  C. Furberg,et al.  Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[62]  S. Nicholls,et al.  Emerging role of intravascular ultrasound in the assessment of experimental anti-atherosclerotic therapies. , 2006, Current medicinal chemistry.

[63]  A. Zwinderman,et al.  Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. , 2003, Archives of internal medicine.

[64]  T Gustavsson,et al.  Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. , 1991, Clinical physiology.

[65]  G. Gallus,et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.

[66]  Fernando Alfonso,et al.  Effects of the Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor Avasimibe on Human Atherosclerotic Lesions , 2004, Circulation.

[67]  P L Allan,et al.  Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. , 1997, Stroke.

[68]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[69]  A. Hughes,et al.  Indian Asian men have less peripheral arterial disease than European men for equivalent levels of coronary disease. , 2007, Atherosclerosis.

[70]  L. Chambless,et al.  High‐Resolution B‐Mode Ultrasound Reading Methods in the Atherosclerosis Risk in Communities (ARIC) Cohort , 1991, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[71]  V. Fuster,et al.  Exploration of the atherosclerotic plaque. , 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[72]  Robert Selzer,et al.  Estrogen in the Prevention of Atherosclerosis , 2001, Annals of Internal Medicine.

[73]  S. Kashiwagi,et al.  Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). , 2002, Journal of the American College of Cardiology.

[74]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[75]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[76]  R W Barnes,et al.  Reproducibility of Noninvasive Ultrasonic Measurement of Carotid Atherosclerosis: The Asymptomatic Carotid Artery Plaque Study , 1992, Stroke.

[77]  H. White,et al.  Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy , 1998 .

[78]  M. Matsuhisa,et al.  Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. , 2000, Thrombosis research.

[79]  P. Bossuyt,et al.  Reduced intima media thickness in adults after prenatal exposure to the Dutch famine. , 2007, Atherosclerosis.

[80]  J. Kastelein,et al.  Surrogate markers of atherosclerosis: impact of statins. , 2003, Atherosclerosis. Supplements.

[81]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[82]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[83]  S. Störk,et al.  Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis: A Randomized, Controlled Trial , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[84]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[85]  P. Poredos,et al.  Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis , 2004, Vascular medicine.

[86]  R H Selzer,et al.  The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.

[87]  Frits Mastik,et al.  Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS). , 2006, Journal of the American College of Cardiology.

[88]  J. Kastelein,et al.  The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[89]  Diederick E Grobbee,et al.  Carotid Intima-Media Thickness Measurements in Intervention Studies: Design Options, Progression Rates, and Sample Size Considerations: A Point of View , 2003, Stroke.

[90]  S. Azen,et al.  Reduction in Carotid Arterial Wall Thickness Using Lovastatin and Dietary Therapy , 1996, Annals of Internal Medicine.

[91]  Allen J. Taylor,et al.  Marked low‐density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis , 2004, Clinical cardiology.

[92]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[93]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[94]  C. H. Liu,et al.  Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. , 1996, Circulation.

[95]  S. Azen,et al.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.

[96]  G. Gamble,et al.  B-mode ultrasound images of the carotid artery wall: correlation of ultrasound with histological measurements. , 1993, Atherosclerosis.

[97]  T. Pearson.  New Tools for Coronary Risk Assessment: What Are Their Advantages and Limitations? , 2002, Circulation.

[98]  J. Witteman,et al.  Carotid intima-media wall thickness in elderly women with and without atherosclerosis of the abdominal aorta. , 1993, Atherosclerosis.

[99]  S. Nissen.  Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. , 2005, The American journal of cardiology.

[100]  Daniel J. Rader,et al.  Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions , 2004, Current atherosclerosis reports.

[101]  A. Zwinderman,et al.  B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). , 1998, Journal of the American College of Cardiology.

[102]  T. Sand,et al.  Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[103]  A. Hofman,et al.  Reproducibility of carotid vessel wall thickness measurements. The Rotterdam Study. , 1994, Journal of clinical epidemiology.

[104]  V. Fuster,et al.  Clinical Imaging of the High-Risk or Vulnerable Atherosclerotic Plaque , 2001, Circulation research.

[105]  R. Pesavento,et al.  Intimal Medial Thickening of Common Carotid Artery as Indicator of Coronary Artery Disease , 1996, Angiology.

[106]  P. Touboul,et al.  Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.

[107]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[108]  Diederick E. Grobbee,et al.  Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin in Subclinical Atherosclerosis—The Rationale and Methodology of the METEOR Study , 2004, Cardiovascular Drugs and Therapy.

[109]  James G Terry,et al.  Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors , 2005, Current controlled trials in cardiovascular medicine.

[110]  G. Belcaro,et al.  Effects of Triflusal on Arteriosclerosis Progression Assessed with High-Resolution Arterial Ultrasound , 1999, Angiology.

[111]  R H Selzer,et al.  Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. , 1996, Circulation.

[112]  E. Eleuteri.  [Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[113]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.